Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of antioxidants in acute amitriptyline poisoning</title><author><name sortKey="Kadar Ali, S Hameed" sort="Kadar Ali, S Hameed" uniqKey="Kadar Ali S" first="S. Hameed" last="Kadar Ali">S. Hameed Kadar Ali</name><affiliation><nlm:aff id="aff0005">Crescent School of Pharmacy, B.S.A Crescent Institute of Science & Technology, Chennai, 6000048, India</nlm:aff></affiliation></author><author><name sortKey="Raja, Wasim Ali" sort="Raja, Wasim Ali" uniqKey="Raja W" first="Wasim Ali" last="Raja">Wasim Ali Raja</name><affiliation><nlm:aff id="aff0010">Dr. Agarwal’s Eye Hospital, Chennai, 600018, India</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31080745</idno><idno type="pmc">6502734</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502734</idno><idno type="RBID">PMC:6502734</idno><idno type="doi">10.1016/j.toxrep.2019.04.002</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000832</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000832</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The effect of antioxidants in acute amitriptyline poisoning</title><author><name sortKey="Kadar Ali, S Hameed" sort="Kadar Ali, S Hameed" uniqKey="Kadar Ali S" first="S. Hameed" last="Kadar Ali">S. Hameed Kadar Ali</name><affiliation><nlm:aff id="aff0005">Crescent School of Pharmacy, B.S.A Crescent Institute of Science & Technology, Chennai, 6000048, India</nlm:aff></affiliation></author><author><name sortKey="Raja, Wasim Ali" sort="Raja, Wasim Ali" uniqKey="Raja W" first="Wasim Ali" last="Raja">Wasim Ali Raja</name><affiliation><nlm:aff id="aff0010">Dr. Agarwal’s Eye Hospital, Chennai, 600018, India</nlm:aff></affiliation></author></analytic><series><title level="j">Toxicology Reports</title><idno type="eISSN">2214-7500</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objective</title><p>To study the effect of Antioxidants supplementation in reducing oxidative stress induced in acute amitriptyline poisoning cases.</p></sec><sec><title>Design and methods</title><p>We compared the effect of supplementation of treatment of acute amitriptyline poisoning cases with alpha lipoic acid alone or with vitamin C, with that of those receiving only routine standard treatment (RST) as a control group.</p><p>A total of 132 subjects divided into 5 groups were selected from IMCU (Intensive Medical Care Unit) and Toxicology Ward, Govt. General Hospital, Chennai, India. The study was restricted to grade 1 coma in poisoned subjects per the Edinburg scale. Each of the subjects was in the groups were supplemented with either placebo, RST, RST with vitamin C, RST with ALA, or RST with vitamin C and ALA.</p><p>Acute anti-depressant poisoning (especially with amitriptyline) induced oxidative stress caused lipid peroxidation. Plasma cholinesterases (chE) play a major role in combating this effect. A determination of the level of cholinesterase (chE) acts as an indirect indicator of the level of oxidative stress and a measure of the efficacy of antioxidant supplementation. Plasma cholinesterase estimation was done by colorimetric method. The change in color of the indicator bromothymol blue caused by the liberated acetic acid from cholinesterase read by spectrophotometer at 620 nm was used to determine the levels of cholinesterase.</p></sec><sec><title>Result</title><p>A decrease in the level of oxidative stress was observed among those supplemented with either alpha lipoic acid alone or along with vitamin C, with a slightly more decrease in oxidative stress in the latter group. A p-value of <0.001 is considered significant statistically. The percentage of the benefit of treatment on supplementation with vitamin C and alpha lipoic acid showed a marked increase in group V (26.9%) cases after supplementation with both in combination.</p></sec><sec><title>Conclusion</title><p>The results provide evidence that the oxidative stress induced by acute amitriptyline poisoning is comparatively decreased by supplementation with antioxidants like alpha lipoic acid and vitamin C, than those only on routine standard treatment.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Morgan, C" uniqKey="Morgan C">C. Morgan</name></author><author><name sortKey="King, R" uniqKey="King R">R. King</name></author><author><name sortKey="Weisz, J" uniqKey="Weisz J">J. Weisz</name></author><author><name sortKey="Schopler, J" uniqKey="Schopler J">J. Schopler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Watson, W" uniqKey="Watson W">W. Watson</name></author><author><name sortKey="Litovitz, T" uniqKey="Litovitz T">T. Litovitz</name></author><author><name sortKey="Rodgers, G" uniqKey="Rodgers G">G. Rodgers</name></author><author><name sortKey="Klein Schwartz, W" uniqKey="Klein Schwartz W">W. Klein-Schwartz</name></author><author><name sortKey="Reid, N" uniqKey="Reid N">N. Reid</name></author><author><name sortKey="Youniss, J" uniqKey="Youniss J">J. Youniss</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jayashree, G" uniqKey="Jayashree G">G. Jayashree</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deavall, D" uniqKey="Deavall D">D. Deavall</name></author><author><name sortKey="Martin, E" uniqKey="Martin E">E. Martin</name></author><author><name sortKey="Horner, J" uniqKey="Horner J">J. Horner</name></author><author><name sortKey="Roberts, R" uniqKey="Roberts R">R. Roberts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Who" uniqKey="Who">WHO</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nishimura, T" uniqKey="Nishimura T">T. Nishimura</name></author><author><name sortKey="Maruguchi, H" uniqKey="Maruguchi H">H. Maruguchi</name></author><author><name sortKey="Nakao, A" uniqKey="Nakao A">A. Nakao</name></author><author><name sortKey="Nakayama, S" uniqKey="Nakayama S">S. Nakayama</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Olson, K" uniqKey="Olson K">K. Olson</name></author><author><name sortKey="Kearney, T" uniqKey="Kearney T">T. Kearney</name></author><author><name sortKey="Dyer, J" uniqKey="Dyer J">J. Dyer</name></author><author><name sortKey="Benowitz, N" uniqKey="Benowitz N">N. Benowitz</name></author><author><name sortKey="Blanc, P" uniqKey="Blanc P">P. Blanc</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guloglu, C" uniqKey="Guloglu C">C. Guloglu</name></author><author><name sortKey="Orak, M" uniqKey="Orak M">M. Orak</name></author><author><name sortKey="Ustundag, M" uniqKey="Ustundag M">M. Ustundag</name></author><author><name sortKey="Altunci, Y" uniqKey="Altunci Y">Y. Altunci</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Halliwell, B" uniqKey="Halliwell B">B. Halliwell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheeseman, K" uniqKey="Cheeseman K">K. Cheeseman</name></author><author><name sortKey="Slater, T" uniqKey="Slater T">T. Slater</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pryor, W" uniqKey="Pryor W">W. Pryor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benzie, I" uniqKey="Benzie I">I. Benzie</name></author><author><name sortKey="Strain, J" uniqKey="Strain J">J. Strain</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bandegi, L" uniqKey="Bandegi L">L. Bandegi</name></author><author><name sortKey="Anvari, M" uniqKey="Anvari M">M. Anvari</name></author><author><name sortKey="Vakili, M" uniqKey="Vakili M">M. Vakili</name></author><author><name sortKey="Khoradmehr, A" uniqKey="Khoradmehr A">A. Khoradmehr</name></author><author><name sortKey="Mirjalili, A" uniqKey="Mirjalili A">A. Mirjalili</name></author><author><name sortKey="Talebi, A" uniqKey="Talebi A">A. Talebi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smirnoff, N" uniqKey="Smirnoff N">N. Smirnoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Padayatty, S" uniqKey="Padayatty S">S. Padayatty</name></author><author><name sortKey="Katz, A" uniqKey="Katz A">A. Katz</name></author><author><name sortKey="Wang, Y" uniqKey="Wang Y">Y. Wang</name></author><author><name sortKey="Eck, P" uniqKey="Eck P">P. Eck</name></author><author><name sortKey="Kwon, O" uniqKey="Kwon O">O. Kwon</name></author><author><name sortKey="Lee, J" uniqKey="Lee J">J. Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Simioni, C" uniqKey="Simioni C">C. Simioni</name></author><author><name sortKey="Zauli, G" uniqKey="Zauli G">G. Zauli</name></author><author><name sortKey="Martelli, A" uniqKey="Martelli A">A. Martelli</name></author><author><name sortKey="Vitale, M" uniqKey="Vitale M">M. Vitale</name></author><author><name sortKey="Sacchetti, G" uniqKey="Sacchetti G">G. Sacchetti</name></author><author><name sortKey="Gonelli, A" uniqKey="Gonelli A">A. Gonelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ganguly, S" uniqKey="Ganguly S">S. Ganguly</name></author><author><name sortKey="Chandra, A" uniqKey="Chandra A">A. Chandra</name></author><author><name sortKey="Chatterjee, I" uniqKey="Chatterjee I">I. Chatterjee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ganguly, S" uniqKey="Ganguly S">S. Ganguly</name></author><author><name sortKey="Chandra, A" uniqKey="Chandra A">A. Chandra</name></author><author><name sortKey="Chattopadhyay, D" uniqKey="Chattopadhyay D">D. Chattopadhyay</name></author><author><name sortKey="Chatterjee, I" uniqKey="Chatterjee I">I. Chatterjee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jaiswal, S" uniqKey="Jaiswal S">S. Jaiswal</name></author><author><name sortKey="Gupta, V" uniqKey="Gupta V">V. Gupta</name></author><author><name sortKey="Ansari, M" uniqKey="Ansari M">M. Ansari</name></author><author><name sortKey="Siddiqi, N" uniqKey="Siddiqi N">N. Siddiqi</name></author><author><name sortKey="Sharma, B" uniqKey="Sharma B">B. Sharma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oliveira, K" uniqKey="Oliveira K">K. Oliveira</name></author><author><name sortKey="Dos Anjos, L" uniqKey="Dos Anjos L">L. dos Anjos</name></author><author><name sortKey="Araujo, A" uniqKey="Araujo A">A. Araújo</name></author><author><name sortKey="Luz, W" uniqKey="Luz W">W. Luz</name></author><author><name sortKey="Kauffmann, N" uniqKey="Kauffmann N">N. Kauffmann</name></author><author><name sortKey="Braga, D" uniqKey="Braga D">D. Braga</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hager, K" uniqKey="Hager K">K. Hager</name></author><author><name sortKey="Marahrens, A" uniqKey="Marahrens A">A. Marahrens</name></author><author><name sortKey="Kenklies, M" uniqKey="Kenklies M">M. Kenklies</name></author><author><name sortKey="Riederer, P" uniqKey="Riederer P">P. Riederer</name></author><author><name sortKey="Munch, G" uniqKey="Munch G">G. Münch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smeyne, M" uniqKey="Smeyne M">M. Smeyne</name></author><author><name sortKey="Smeyne, R" uniqKey="Smeyne R">R. Smeyne</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Venkataraman, B V" uniqKey="Venkataraman B">B.V. Venkataraman</name></author><author><name sortKey="Naga Rani, M A" uniqKey="Naga Rani M">M.A. Naga Rani</name></author><author><name sortKey="Andrade, C" uniqKey="Andrade C">C. Andrade</name></author><author><name sortKey="Joseph, T" uniqKey="Joseph T">T. Joseph</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burtis, C" uniqKey="Burtis C">C. Burtis</name></author><author><name sortKey="Ashwood, E" uniqKey="Ashwood E">E. Ashwood</name></author><author><name sortKey="Tietz, N" uniqKey="Tietz N">N. Tietz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Miller, N" uniqKey="Miller N">N. Miller</name></author><author><name sortKey="Rice Evans, C" uniqKey="Rice Evans C">C. Rice-Evans</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nikalje, A" uniqKey="Nikalje A">A. Nikalje</name></author><author><name sortKey="Bhosale, D" uniqKey="Bhosale D">D. Bhosale</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Flanagan, R" uniqKey="Flanagan R">R. Flanagan</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Bielski, B H J" uniqKey="Bielski B">B.H.J. Bielski</name></author><author><name sortKey="Comstock, D A" uniqKey="Comstock D">D.A. Comstock</name></author><author><name sortKey="Bowen, R A J" uniqKey="Bowen R">R.A.J. Bowen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Demling, R" uniqKey="Demling R">R. Demling</name></author><author><name sortKey="Lalonde, C" uniqKey="Lalonde C">C. Lalonde</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martell, A" uniqKey="Martell A">A. Martell</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Toxicol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Toxicol Rep</journal-id><journal-title-group><journal-title>Toxicology Reports</journal-title></journal-title-group><issn pub-type="epub">2214-7500</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31080745</article-id><article-id pub-id-type="pmc">6502734</article-id><article-id pub-id-type="publisher-id">S2214-7500(19)30205-7</article-id><article-id pub-id-type="doi">10.1016/j.toxrep.2019.04.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The effect of antioxidants in acute amitriptyline poisoning</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Kadar Ali</surname><given-names>S. Hameed</given-names></name><email>kadarali@crescent.education</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="cor0005" ref-type="corresp">⁎</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Raja</surname><given-names>Wasim Ali</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>Crescent School of Pharmacy, B.S.A Crescent Institute of Science & Technology, Chennai, 6000048, India</aff><aff id="aff0010"><label>b</label>Dr. Agarwal’s Eye Hospital, Chennai, 600018, India</aff><author-notes><corresp id="cor0005"><label>⁎</label>Corresponding author. <email>kadarali@crescent.education</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>16</day><month>4</month><year>2019</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>16</day><month>4</month><year>2019</year></pub-date><volume>6</volume><fpage>380</fpage><lpage>388</lpage><permissions><copyright-statement>© 2019 Published by Elsevier B.V.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder></copyright-holder><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0005"><sec><title>Objective</title><p>To study the effect of Antioxidants supplementation in reducing oxidative stress induced in acute amitriptyline poisoning cases.</p></sec><sec><title>Design and methods</title><p>We compared the effect of supplementation of treatment of acute amitriptyline poisoning cases with alpha lipoic acid alone or with vitamin C, with that of those receiving only routine standard treatment (RST) as a control group.</p><p>A total of 132 subjects divided into 5 groups were selected from IMCU (Intensive Medical Care Unit) and Toxicology Ward, Govt. General Hospital, Chennai, India. The study was restricted to grade 1 coma in poisoned subjects per the Edinburg scale. Each of the subjects was in the groups were supplemented with either placebo, RST, RST with vitamin C, RST with ALA, or RST with vitamin C and ALA.</p><p>Acute anti-depressant poisoning (especially with amitriptyline) induced oxidative stress caused lipid peroxidation. Plasma cholinesterases (chE) play a major role in combating this effect. A determination of the level of cholinesterase (chE) acts as an indirect indicator of the level of oxidative stress and a measure of the efficacy of antioxidant supplementation. Plasma cholinesterase estimation was done by colorimetric method. The change in color of the indicator bromothymol blue caused by the liberated acetic acid from cholinesterase read by spectrophotometer at 620 nm was used to determine the levels of cholinesterase.</p></sec><sec><title>Result</title><p>A decrease in the level of oxidative stress was observed among those supplemented with either alpha lipoic acid alone or along with vitamin C, with a slightly more decrease in oxidative stress in the latter group. A p-value of <0.001 is considered significant statistically. The percentage of the benefit of treatment on supplementation with vitamin C and alpha lipoic acid showed a marked increase in group V (26.9%) cases after supplementation with both in combination.</p></sec><sec><title>Conclusion</title><p>The results provide evidence that the oxidative stress induced by acute amitriptyline poisoning is comparatively decreased by supplementation with antioxidants like alpha lipoic acid and vitamin C, than those only on routine standard treatment.</p></sec></abstract><kwd-group id="kwd0005"><title>Abbreviations</title><kwd>RST, routine standard treatment</kwd><kwd>IMCU, intensive medical care unit</kwd></kwd-group><kwd-group id="kwd0010"><title>Keywords</title><kwd>Alpha lipoic acid (ALA)</kwd><kwd>Cholinesterase (chE)</kwd><kwd>Oxidative stress</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="par0005">Acute anti-depressant poisoning is a common and urgent medical problem in all developed, and many developing, countries of the world. In the United Kingdom, it accounts for 15–20% of all acute medical emergency admissions to hospital. The different types of acute poisoning are accidental (10%) and intentional (90%). In the intentional type, only 20% are actual attempted suicide cases and 80% are self-poisoning cases. In older age groups the great majority are intentional. Acute poisoning is more common in females than in males in all age groups, the ratio of females to males being about 1.4: 1.0. The increase has been marked in patients of lower social class [<xref rid="bib0005" ref-type="bibr">1</xref>]. In 2004, the Toxic Exposure Surveillance System (TESS) national database of poison center maintained by the American Association of Poison Control Centers (AAPCC) recorded 7,430 exposures to amitriptyline, 4804 to other cyclic antidepressants. Of the 12,234 exposures, there were 1,351 (9%) exposures in children less than 6 years of age and 3,881 (32%) exposures described as unintentional. A total of 9,324 (76%) exposures were treated in healthcare facilities [<xref rid="bib0010" ref-type="bibr">2</xref>]. This increased referral rate shows the potential toxicity of this class of drugs.</p><p id="par0010">The drugs used to treat psychiatric disorders are known collectively as psychotropics [<xref rid="bib0015" ref-type="bibr">3</xref>]. They are classified according to their main mode of action into:<list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>I</label><p id="par0015">IAnti-psychotic drugs (Major Tranquilizers) – Ex: Chlorpromazine</p></list-item><list-item id="lsti0010"><label>II</label><p id="par0020">II Anti-anxiety drugs – Ex: Alprazolam and diazepam</p></list-item><list-item id="lsti0015"><label>III</label><p id="par0025">IIIPsychotogenic or Psychodelic drugs – Ex: LSD, cannabis, atropine</p></list-item><list-item id="lsti0020"><label>IV</label><p id="par0030">IVAntidepressant drugs – Ex: Amitriptyline, Nortriptyline</p></list-item></list></p><p id="par0035">Drug-induced oxidative stress is a well-studied phenomenon especially those of chlorpromazine-induced phototoxicity, by the generation of reactive oxygen species (ROS) [<xref rid="bib0020" ref-type="bibr">4</xref>]. Antipsychotics are majorly notorious for their severe adverse effects compared to other classes of psychotropic drugs. Anti-depressants and anti-anxiety drugs are more frequently available over the counter and are frequent sources of abuse compared to antipsychotics with no major visibly manifest toxicity. Yet, their damage potential is comparable to that of antipsychotics as far as oxidative stress induced tissue damage is concerned.</p><p id="par0040">Amitriptyline a 3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-ylidene)-<italic>N, N</italic>-dimethylpropane-1-amine with a chemical formula of C<sub>20</sub>H<sub>23</sub>N and a molecular weight of 277.403 g/mol, is a very widely used tricyclic antidepressant. It is metabolized by <italic>N</italic>-demethylation to nortriptyline, latter is an antidepressant in its own right [<xref rid="bib0025" ref-type="bibr">5</xref>]. Amitriptyline is used in the treatment of depression, fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, and atypical facial pain. Amitriptyline exerts its antidepressant action by blocking the neuronal reuptake of noradrenaline and serotonin. Amitriptyline has significant anticholinergic activity and some sedative action. Amitriptyline is easily available and commonly abused for suicidal purposes in developing countries.</p><p id="par0045">Amitriptyline can cause serious complications, such as compartment syndrome of abdominal viscera, irreversible damage to the central nervous system and lethal ventricular tachycardia. [<xref rid="bib0030" ref-type="bibr">6</xref>] It also has a key role in tissue damage especially the central nervous and cardiovascular systems via free radical-induced oxidative stress [<xref rid="bib0035" ref-type="bibr">7</xref>]. In a series of 110 cases of overdose by amitriptyline for suicide attempts by adult single women admitted to the emergency department of Dicle University Hospital, Turkey (Güloglu C et al). The most common symptoms were sinus tachycardia (66.3%), altered mental state (78.1%) and hypotension (7.3%). Mechanical ventilator support was required in 9.1% of cases [<xref rid="bib0040" ref-type="bibr">8</xref>].</p><sec id="sec0010"><label>1.1</label><title>Oxidative stress</title><p id="par0050">The term oxidative stress refers to the situation of an altered interplay between the production of free radicals and antioxidant defense [<xref rid="bib0045" ref-type="bibr">9</xref>]. Oxidative stress in human can result in diminished antioxidant efficacy, when the free radical production overwhelms the endogenous antioxidant levels like glutathione, thereby causing considerable cell damage or death via apoptosis. It is responsible for various systemic disorders like Parkinsonism, Alzheimer’s disease, myocardial infarction, depression, sickle cell disease, and autism and ADHD (Attention-deficit/Hyperactivity Disorder) in children.</p><p id="par0055">All major biomolecules like lipids, proteins, and nucleic acids react with free radicals, but lipids are probably the most susceptible [<xref rid="bib0050" ref-type="bibr">10</xref>]. The polyunsaturated fatty acids, like arachidonic acid and linoleic acid, are the major targets for free radical oxidation. The oxidative destruction of lipids (lipid peroxidation) is a destructive self-perpetuating chain reaction releasing malonyldialdehyde (MDA) as the end product [<xref rid="bib0055" ref-type="bibr">11</xref>].</p><p id="par0060">Antioxidants such as catalase, superoxide dismutase (SOD), glutathione, sulfiredoxin glutathione-S transferases, and aldehyde dehydrogenases are potent free radical scavengers. Unlike in-vivo antioxidants, certain dietary antioxidants not synthesized by human bodies like vitamin A (beta-carotene), vitamin E (tocopherol), vitamin B12 (cholecalciferol) and alpha lipoic acid potentiate the free radical scavenging ability of these in vivo antioxidants.</p><p id="par0065">Studies have shown that in acute amitriptyline poisoning cases, there is an increased level of SOD, MDA and reduced antioxidant capacity of blood (FRAP assay) [<xref rid="bib0060" ref-type="bibr">12</xref>]. An increased production of reactive oxygen species due to excessive intake of amitriptyline leading to an increase in tissue oxidative stress and tissue structural and functional damage has been documented [<xref rid="bib0065" ref-type="bibr">13</xref>].</p></sec><sec id="sec0015"><label>1.2</label><title>Vitamin C</title><p id="par0070">Ascorbic acid (vitamin C) is a monosaccharide antioxidant found in both animals and plants, [<xref rid="bib0070" ref-type="bibr">14</xref>] is vital for the conversion of procollagen to collagen, the formation of norepinephrine from dopamine, carnitine synthesis and metabolism of tyrosine. Vitamin C is one of the popular, extensively studied, and the widely supplemented antioxidant. It works even better in conjunction with other antioxidants, such as alpha lipoic acid and carotenoids, by establishing a peculiar recycling system with a synergic effect.</p><p id="par0075">In its reduced form with glutathione, it acts as a redox catalyst which can reduce, and thereby neutralize, reactive oxygen species such as hydrogen peroxide [<xref rid="bib0075" ref-type="bibr">15</xref>]. Ascorbate acts as an electron donor in all these reactions thereby itself getting oxidized. Ascorbic acid has shown promising results in the management of drug inducted oxidative stress damage to tissue in various animal models [<xref rid="bib0080" ref-type="bibr">16</xref>].</p><p id="par0080">Apart from the aforementioned antioxidant properties of vitamin C, it does also posses anti carcinogenic effect such as those in the prevention of cigarette smoking and its major derivative p-Benzoquinone induced oxidative damage in urothelial cancer of the renal pelvis, ureter and bladder [<xref rid="bib0085" ref-type="bibr">17</xref>,<xref rid="bib0090" ref-type="bibr">18</xref>]. It also act as a hepato-protectant in various pesticide toxicity like carbofuran induced free radical damage and increased lipid per-oxidation in rat liver models at low concentration intoxication [<xref rid="bib0095" ref-type="bibr">19</xref>]. Furthermore, vitamin C also protects from chloroquine induced oto-toxicity, a drug commonly used as anti-lupus and anti-malarial agent [<xref rid="bib0100" ref-type="bibr">20</xref>]. Such versatile is the action of vitamin C in biological tissue protection from oxidative damage.</p></sec><sec id="sec0020"><label>1.3</label><title>Alpha lipoic acid</title><p id="par0085">Alpha lipoic acid initially classified as a vitamin was discovered three decades earlier and possessed potent antioxidant properties. It is more potent than the old guard antioxidants like vitamin C and E; it even recycles these vitamins and enhances their effectiveness. In addition to functioning as an antioxidant, it also assists B vitamins in producing energy from the proteins, carbohydrates, and fats consumed through foods. It has properties of both lipid and water solubility, thereby facilitating its reach into tissues composed of fat, such as the nervous system as well as those mainly of water such as the cardiovascular system.</p><p id="par0090">A study conducted with 600 mg of alpha lipoic acid given daily to nine Alzheimer's patients, on an average for 80 days lead to stabilization of cognitive functions in the Alzheimer's study group. This was the first indication that alpha lipoic acid might be a successful neuroprotective therapy option for Alzheimer diseases and related dementias [<xref rid="bib0105" ref-type="bibr">21</xref>].</p><p id="par0095">In animal studies, alpha lipoic acid has been seen to increase the blood flow to the nerves and improved transmission of nerve impulses. Parkinson's disease, a disorder of the central nervous system, is characterized clinically by spontaneous movements, gait difficulties, postural instability, rigidity, and tremor. Oxidative stress plays a major role in neuronal degeneration associated with Parkinson’s disease. Depletion of glutathione (GSH) in the brain is the earliest indicator of oxidative stress in presymptomatic Parkinson’s disease [<xref rid="bib0110" ref-type="bibr">22</xref>].</p><p id="par0100">Studies in both in-vitro and in-vivo models have suggested that pretreatment with alpha lipoic acid increase cellular levels of GSH, probably by preventing its depletion thereby protecting mitochondria integrity. Results with previous studies suggest that alpha lipoic acid may be an effective neuroprotective agent in age-associated neurodegeneration utilizing the PC12 cell model system.</p><p id="par0105">Based on the above beneficial effects of alpha lipoic acid on nervous system it has been decided to supplement alpha lipoic acid in acute amitriptyline poisoning cases, which have increased oxidative stress and neurotoxicity and study the effect after supplementation.</p></sec></sec><sec id="sec0025"><label>2</label><title>Subjects and methods</title><p id="par0110">A total of 132 subjects were enrolled for the study and were divided into 5 groups. They were selected from IMCU and Toxicology Ward, Govt. General Hospital between Sept. 2005 and March 2008. Consent was obtained from the attendants of the patients. The study was approved by the Ethical committee of Madras Medical College, Chennai.</p><sec id="sec0030"><label>2.1</label><title>Inclusion criteria</title><p id="par0115">The Patient selection was done randomly. The Edinburgh scale was used to classify the depth or grade of the coma of poisoned patients, graded as under:-</p><p id="par0120">Grade 1:Patient drowsy but responding to verbal commands.</p><p id="par0125">Grade 2:Patient unconscious but responding to minimal stimuli</p><p id="par0130">(For example, shaking, shouting)</p><p id="par0135">Grade 3:Patient unconscious and responding only to painful stimuli</p><p id="par0140">(For example, rubbing the sternum)</p><p id="par0145">Grade 4:Patient unconscious with no response to any stimuli</p><p id="par0150">The study was restricted only to the grade 1 patients from IMCU.</p><p id="par0155">The groups were classified as follows:<list list-type="simple" id="lis0010"><list-item id="lsti0025"><label>•</label><p id="par0160"><bold>Group I:</bold> Consisted of 30 healthy volunteers (15 males and 15 females) mean age 32 years.</p></list-item><list-item id="lsti0030"><label>•</label><p id="par0165"><bold>Group II:</bold> Consisted of 30 patients (18 males and 12 females) mean age 34 years. These patients received only Routine Standard Treatment (RST)</p></list-item><list-item id="lsti0035"><label>•</label><p id="par0170"><bold>Group III:</bold> Consisted of 21 patients (12 males and 9 females) mean age 32 years. These patients received (RST) + vitamin C supplementation.</p></list-item><list-item id="lsti0040"><label>•</label><p id="par0175"><bold>Group IV:</bold> Consisted of 27 patients (13 males and 14 females), mean age 31 years. These patients received (RST) + alpha lipoic acid supplementation.</p></list-item><list-item id="lsti0045"><label>•</label><p id="par0180"><bold>Group V:</bold> Consisted of 24 patients (14 males and 10 females), mean age 34 years. These patients received (RST) + vitamin C and alpha lipoic acid supplementation.</p></list-item></list></p><p id="par0185">The basal level of oxidative stress markers and enzymatic and non–enzymatic antioxidants were measured at the beginning of the treatment and followed up until the day of discharge from IMCU.</p></sec><sec id="sec0035"><label>2.2</label><title>Exclusion criteria</title><p id="par0400"><list list-type="simple" id="lis0015"><list-item id="lsti0050"><label>•</label><p id="par0190">Subjects with age less than 18 years and more than 60 years were not included in this study, considering the confounding effect of hormonal and metabolic alterations.</p></list-item><list-item id="lsti0055"><label>•</label><p id="par0195">Patients those who have taken other drugs along with amitriptyline were not included in this study, due to cross interference.</p></list-item><list-item id="lsti0060"><label>•</label><p id="par0200">Patients with TLC (Thin Layer Chromatography) positive and spectra (uv–vis) negative were not included in this study.</p></list-item></list></p></sec><sec id="sec0040"><label>2.3</label><title>Sample collection</title><p id="par0205">10 ml of venous blood was drawn from the antecubital vein of each experimental subject. 5 ml of blood was collected in a plain tube for enzyme analysis and 5 ml in a sterile heparin vacutainer tubes. The plasma was separated by centrifugation at 1500 x g for 10 min and stored in new clean storage vials at - 80 °C to be used for analysis of antioxidants and plasma cholinesterase. The cells were separated and washed with normal saline and RBCs were subjected to lysis and used for RBC cholinesterase estimation.</p><p id="par0210">50 ml of gastric aspirate was collected from all patients who are directly admitted to IMCU and poison center GGH, Chennai-3. This gastric aspirate was taken for TLC identification.</p></sec><sec id="sec0045"><label>2.4</label><title>Methods</title><sec id="sec0050"><label>2.4.1</label><title>Cholinesterase estimation</title><sec id="sec0055"><label>2.4.1.1</label><title>Plasma cholinesterase</title><p id="par0215">The cholinesterase levels were determined from both the centrifuge derived plasma and the substrate from RBC lysate. Estimation was done by colorimetric method using acetylcholine as substrate (Venkataraman et al) [<xref rid="bib0115" ref-type="bibr">23</xref>]. Both true and pseudo cholinesterase would hydrolyze the substrate and produce choline and acetic acid. The change in color of the indicator, bromothymol blue caused by the liberated acetic acid from cholinesterase was read by spectrophotometer at 620 nm.</p><p id="par0220">Bromothymol blue 0.5 ml solution was diluted with 3.8 ml of distilled water and 0.2 ml of 15% acetylcholine chloride was added. About 100 μl of plasma was added to it and the change in color was read at 620 nm at 37-degree c after 30 min. A standard graph was plotted using acetic acid 0.15 N in the concentration of 10, 20, 50,100 and 200 μmol.</p></sec><sec id="sec0060"><label>2.4.1.2</label><title>RBC cholinesterase</title><p id="par0225">The RBCs were extracted by adding 3 ml of distilled water followed by precipitation of hemoglobin with acetone 2 ml and centrifugation at 3000 rpm. The supernatant was used for estimation of RBC Cholinesterase in a similar fashion.</p></sec></sec><sec id="sec0065"><label>2.4.2</label><title>Vitamin C estimation</title><p id="par0230">Ascorbic acid in plasma was oxidized by Cu2+ to form a dehydro-ascorbic acid that reacts with acidic 2, 4 dinitrophenyl hydrazine to form red bis-hydrazone, which was measured spectrophotometrically by 2,4 dinitrophenylhydrazine method. The concentration of ascorbic acid in plasma was determined using a standard curve [<xref rid="bib0120" ref-type="bibr">24</xref>].</p></sec><sec id="sec0070"><label>2.4.3</label><title>Total antioxidant status</title><p id="par0235">Total antioxidant status of the sample was measured by a commercial kit, supplied by the Randox Laboratories.</p><p id="par0240"><underline>Principle:</underline> ABTS<sup>+</sup> (2-2′ – Azino-di-[ethylbenzthiazoline sulphonate] is incubated with a peroxidase (metmyoglobin) and H<sub>2</sub>O<sub>2</sub> to produce the radical cation ABTS<sup>+</sup>. This has a relatively stable blue-green color, when measured at 600 nm Antioxidants in the added sample cause suppression of this color production to a degree which was proportional to their concentrations [<xref rid="bib0125" ref-type="bibr">25</xref>].</p><p id="par0245">20 μl of plasma was added to 1 ml of chromogen and incubated at room temperature for 1 min. The initial Absorbance (A<sub>1</sub>) was measured at 600 nm Another 200 μl of substrate added to it and incubated at room temperature for 3 min and the final absorbance A<sub>2</sub> was measured again at 600 nm A Blank and a Standard were run simultaneously, and the initial absorbance A<sub>1</sub> and final absorbance A<sub>2</sub> was measured at 600 nm for both the blank and standard respectively.</p><p id="par0250">A<sub>2</sub>-A<sub>1</sub> =ΔA of the sample/ blank/ standard were individually determined,<disp-formula id="eq0005"><mml:math id="M1" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:mtext>Factor</mml:mtext><mml:mtext> </mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mtext>Concentration of the standard</mml:mtext><mml:mrow><mml:mtext>ΔA blank</mml:mtext><mml:mo>–</mml:mo><mml:mtext>ΔA standard</mml:mtext></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p id="par0255">Total Antioxidant status in m.mol/l = Factor X (ΔA blank-ΔA sample)</p></sec><sec id="sec0075"><label>2.4.4</label><title>Drug extraction from stomach wash contents for TLC</title><p id="par0260">The stomach wash contents obtained from the patient who has been suspected to have consumed drug was taken for TLC analysis, 10 ml of the collected stomach wash contents was taken in the vortex tube of 11 cm length and 2.5 cm diameter and equal volume of 10 ml of chloroform: propane-2-ol (9:1) mixture which was allowed to stand for 5 min was added. The solution was thoroughly mixed by the vortex mixer (cyclomixer) for about 5–10 minutes.</p><p id="par0265">The mixed solution was poured into a separating funnel and allowed to stand for 30–45 min for the aqueous and organic layer to separate. The drug compound suspected get extracted into the chloroform layer, which remained at the bottom of the separating funnel. The separated organic layer containing chloroform and drug was removed from the separating funnel by slowly opening the knob; whereby the lower layer was allowed to run into a funnel with a filter paper containing 2 gm of sodium sulfite, which removes the water molecules and polar substances from the layer. The rest of the solution is poured into a beaker and evaporated to near dryness in a water bath at 60°c. Few drops of chloroform were added in the breaker and the extract was ready for application on a TLC.</p></sec><sec id="sec0080"><label>2.4.5</label><title>TLC (thin layer chromatography) application</title><p id="par0270">About 5 μl of the extracted sample was spotted on to a TLC plate at a position of 2.0–2.5 cm from the bottom edge of the plate with a help of a specialized capillary tube. The circular spot about 2–6 mm in diameter was spotted on a line parallel to the standard drug substance. The two spots of standard and test sample were plotted at a distance of more than 1.5 cm to prevent any smearing [<xref rid="bib0130" ref-type="bibr">26</xref>,<xref rid="bib0135" ref-type="bibr">27</xref>].</p></sec><sec id="sec0085"><label>2.4.6</label><title>Calculation of Rf (relative front or ratio front)</title><p id="par0275">The distance traveled by the solvent mixer is marked and measured in cm. Next, the distance traveled by the solute is marked as a rounded spot. The distance from the center of the spot to the point of its spotting, measured in cm is the distance traveled by the solute.</p><p id="par0280">Rf value for the drug was calculated using the following formula.<disp-formula id="eq0010"><mml:math id="M2" altimg="si2.gif" overflow="scroll"><mml:mrow><mml:mtext>Rf</mml:mtext><mml:mtext> </mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mtext>Distance travel by solute in cm</mml:mtext><mml:mtext>Distance travel by solvent in cm</mml:mtext></mml:mfrac></mml:mrow></mml:math></disp-formula></p></sec></sec></sec><sec id="sec0090"><label>3</label><title>Statistical analysis</title><p id="par0285">Statistical evaluation was carried out using SPSS (14.0). Data obtained from the study groups were compared by the parametric student's t-test. A correlation analysis between the variables was made by Pearson test and a P value of <0.001 was considered statistically significant.</p><p id="par0290">The effect of vitamin C, alpha lipoic acid and both combined were analyzed for each group and expressed as a percentage of benefit with and without supplementation of vitamin C, alpha lipoic acid and both combined. Multiple comparisons of each group with the normal were carried out using the Bonferroni corrected t-test [<xref rid="bib0070" ref-type="bibr">14</xref>].</p></sec><sec id="sec0095"><label>4</label><title>Results</title><p id="par0295">Identification of amitriptyline overdoses in gastric aspirate in all cases admitted directly to Intensive Medical Care Unit (IMCU) and toxicology ward, Government General Hospital between September 2005 and March 2008 are carried out by TLC. The samples along with controls were run simultaneously and based on their Rf values in the TLC chromatogram, the level of amitriptyline overdose and antioxidant effect were evaluated in all the groups.</p><p id="par0300">The mean levels of plasma Cholinesterase on admission compared with those on discharge in all groups, showed significantly higher values in the latter. (<xref rid="tbl0005" ref-type="table">Table 1</xref>) The percentage of benefit of treatment before and after supplementation with vitamin C showed a significant decrease in group III (39.67 (22.8%)) when compared with group II (45.40(26.1%)). Group V showed a marked improvement (70.0(40.3%)) when compared with group II (45.40(26.1%)). (<xref rid="fig0005" ref-type="fig">Chart 1</xref>, <xref rid="fig0025" ref-type="fig">Chart 5</xref>) Even though the values of plasma Cholinesterase increased on discharge it was not up to the levels of normal individuals (i.e. group I).<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Comparison of levels (in μ/ml) and the percentage of benefit of different methods of treatment on plasma Cholinesterase.</p></caption><alt-text id="at0030">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="2">Groups</th><th colspan="2" align="left">On Admission<hr></hr></th><th colspan="2" align="left">On Discharge<hr></hr></th><th align="left" valign="middle" rowspan="2">Pl. ChE gain</th><th align="left" valign="middle" rowspan="2">Students Paired t-test</th></tr><tr><th align="left">Mean</th><th align="left">SD</th><th align="left">Mean</th><th align="left">SD</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="3"><bold>Normal (I)</bold></td><td align="left" valign="middle" rowspan="3">174.00</td><td align="left" valign="middle" rowspan="3">8.93</td><td align="left" valign="middle" rowspan="3">174.00</td><td align="left" valign="middle" rowspan="3">8.93</td><td align="left" valign="middle" rowspan="3">0.00</td><td align="left">t = 0.00</td></tr><tr><td align="left">p = 1.00</td></tr><tr><td align="left">Not significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment (II)</bold></td><td align="left" valign="middle" rowspan="3">70.07 (40.30%)</td><td align="left" valign="middle" rowspan="3">8.31</td><td align="left" valign="middle" rowspan="3">115.47 (66.40%)</td><td align="left" valign="middle" rowspan="3">11.59</td><td align="left" valign="middle" rowspan="3">45.40 (26.10%)</td><td align="left">t = 16.73</td></tr><tr><td align="left">p = 0.001</td></tr><tr><td align="left">Significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment + VitC (III)</bold></td><td align="left" valign="middle" rowspan="3">90.71 (52.10%)</td><td align="left" valign="middle" rowspan="3">13.71</td><td align="left" valign="middle" rowspan="3">130.38 (74.90%)</td><td align="left" valign="middle" rowspan="3">23.39</td><td align="left" valign="middle" rowspan="3">39.67 (22.80 %)</td><td align="left">t = 7.81</td></tr><tr><td align="left">p = 0.001</td></tr><tr><td align="left">Significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment + ALA (IV)</bold></td><td align="left" valign="middle" rowspan="3">82.81 (47.60%)</td><td align="left" valign="middle" rowspan="3">7.39</td><td align="left" valign="middle" rowspan="3">116.07 (66.70%)</td><td align="left" valign="middle" rowspan="3">13.01</td><td align="left" valign="middle" rowspan="3">33.26 (19.1%)</td><td align="left">t = 12.16</td></tr><tr><td align="left">p = 0.001</td></tr><tr><td align="left">Significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment + ALA + VitC (V)</bold></td><td align="left" valign="middle" rowspan="3">62.54 (35.90%)</td><td align="left" valign="middle" rowspan="3">12.18</td><td align="left" valign="middle" rowspan="3">132.54 (76.20%)</td><td align="left" valign="middle" rowspan="3">23.24</td><td align="left" valign="middle" rowspan="3">70.00 (40.30%)</td><td align="left">t = 12.89</td></tr><tr><td align="left">p = 0.001</td></tr><tr><td align="left">Significant</td></tr></tbody></table></table-wrap><fig id="fig0005"><label>Chart 1</label><caption><p>Comparison of levels of plasma Cholinesterase on different methods of treatment.</p></caption><alt-text id="at0005">Chart 1</alt-text><graphic xlink:href="pl1"></graphic></fig></p><p id="par0305">The mean levels of RBC Cholinesterase on admission compared with those on discharge in all groups, showed significantly higher values on discharge. (<xref rid="tbl0010" ref-type="table">Table 2</xref>) Though the levels of RBC Cholinesterase showed an increase at the time of discharge it was not up to the level of normal individuals. The percentage of the benefit of treatment on supplementation with vitamin C and alpha lipoic acid showed a slight increase in group III (40.57(12.8%)) and group IV (47.7(15.0%)) when compared with group II (33.13(10.5%)) without supplementation (<xref rid="fig0010" ref-type="fig">Chart 2</xref>, <xref rid="fig0025" ref-type="fig">Chart 5</xref>). But the marked increase was observed in group V (85.38(26.9%)) cases after supplementation with vitamin C and alpha lipoic acid in combination.<table-wrap position="float" id="tbl0010"><label>Table 2</label><caption><p>Comparison of levels (in μ/ml) and the percentage of benefit of different methods of treatment on RBC Cholinesterase.</p></caption><alt-text id="at0035">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="2">Groups</th><th colspan="2" align="left">On Admission<hr></hr></th><th colspan="2" align="left">On Discharge<hr></hr></th><th align="left" valign="middle" rowspan="2">RBC ChE gain</th><th align="left" valign="middle" rowspan="2">Students Paired t-test</th></tr><tr><th align="left">Mean</th><th align="left">SD</th><th align="left">Mean</th><th align="left">SD</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="3"><bold>Normal (I)</bold></td><td align="left" valign="middle" rowspan="3">317.33</td><td align="left" valign="middle" rowspan="3">27.65</td><td align="left" valign="middle" rowspan="3">317.33</td><td align="left" valign="middle" rowspan="3">27.65</td><td align="left" valign="middle" rowspan="3">0.00</td><td align="left">t = 0.00</td></tr><tr><td align="left">p = 1.00</td></tr><tr><td align="left">Not significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment (II)</bold></td><td align="left" valign="middle" rowspan="3">142.23 (44.80%)</td><td align="left" valign="middle" rowspan="3">9.71</td><td align="left" valign="middle" rowspan="3">175.37 (55.30%)</td><td align="left" valign="middle" rowspan="3">13.39</td><td align="left" valign="middle" rowspan="3">33.13 (10.50%)</td><td align="left">t = 11.69</td></tr><tr><td align="left">p = 0.001</td></tr><tr><td align="left">Significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment + VitC (III)</bold></td><td align="left" valign="middle" rowspan="3">182.62 (57.50%)</td><td align="left" valign="middle" rowspan="3">25.79</td><td align="left" valign="middle" rowspan="3">223.19 (70.30%)</td><td align="left" valign="middle" rowspan="3">34.31</td><td align="left" valign="middle" rowspan="3">40.57 (12.80%)</td><td align="left">t = 6.46</td></tr><tr><td align="left">p = 0.001</td></tr><tr><td align="left">Significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment + ALA (IV)</bold></td><td align="left" valign="middle" rowspan="3">150.81 (47.50%)</td><td align="left" valign="middle" rowspan="3">32.09</td><td align="left" valign="middle" rowspan="3">198.52 (62.50%)</td><td align="left" valign="middle" rowspan="3">42.98</td><td align="left" valign="middle" rowspan="3">47.70 (15.00%)</td><td align="left">t = 5.88</td></tr><tr><td align="left">p = 0.001</td></tr><tr><td align="left">Significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment + ALA + VitC (V)</bold></td><td align="left" valign="middle" rowspan="3">146.71 (46.20%)</td><td align="left" valign="middle" rowspan="3">9.88</td><td align="left" valign="middle" rowspan="3">232.08 (73.10%)</td><td align="left" valign="middle" rowspan="3">47.89</td><td align="left" valign="middle" rowspan="3">85.38 (26.90%)</td><td align="left">t = 9.06</td></tr><tr><td align="left">p = 0.001</td></tr><tr><td align="left">Significant</td></tr></tbody></table></table-wrap><fig id="fig0010"><label>Chart 2</label><caption><p>Comparison of levels of RBC Cholinesterase on different methods of treatment.</p></caption><alt-text id="at0010">Chart 2</alt-text><graphic xlink:href="pl2"></graphic></fig></p><p id="par0310">The mean levels of MDA in all groups on admission compared with those on discharge, showed an increase in MDA levels on admission and the increase continued till discharge in all groups except in group V cases (<xref rid="tbl0015" ref-type="table">Table 3</xref>, <xref rid="fig0015" ref-type="fig">Chart 3</xref>). In group V cases though the levels at the time of discharge decreased, the decrease though was meager, was significant. The benefit of treatment on MDA showed improvement in group V cases and the levels of MDA decreased on combined supplementation with antioxidants in this group (<xref rid="fig0015" ref-type="fig">Chart 3</xref>, <xref rid="fig0025" ref-type="fig">Chart 5</xref> i.e. 2.10 to 2.01(−0.08)).<table-wrap position="float" id="tbl0015"><label>Table 3</label><caption><p>Comparison of levels (in moles/ml) and the percentage of benefit of different methods of treatment on Malonyldialdehyde (MDA).</p></caption><alt-text id="at0040">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="2">Groups</th><th colspan="2" align="left">On Admission<hr></hr></th><th colspan="2" align="left">On Discharge<hr></hr></th><th align="left" valign="middle" rowspan="2">MDA level</th><th align="left" valign="middle" rowspan="2">Students Paired t-test</th></tr><tr><th align="left">Mean</th><th align="left">SD</th><th align="left">Mean</th><th align="left">SD</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="3"><bold>Normal (I)</bold></td><td align="left" valign="middle" rowspan="3">1.26</td><td align="left" valign="middle" rowspan="3">0.08</td><td align="left" valign="middle" rowspan="3">1.26</td><td align="left" valign="middle" rowspan="3">0.08</td><td align="left" valign="middle" rowspan="3">0.00</td><td align="left">t = 0.00</td></tr><tr><td align="left">p = 1.00</td></tr><tr><td align="left">Not significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment (II)</bold></td><td align="left" valign="middle" rowspan="3">2.03 (161%)</td><td align="left" valign="middle" rowspan="3">0.89</td><td align="left" valign="middle" rowspan="3">2.37 (188%)</td><td align="left" valign="middle" rowspan="3">0.63</td><td align="left" valign="middle" rowspan="3">0.34 (26.90%)</td><td align="left">t = 3.27</td></tr><tr><td align="left">p = 0.003</td></tr><tr><td align="left">Significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment + VitC (III)</bold></td><td align="left" valign="middle" rowspan="3">2.20 (175%)</td><td align="left" valign="middle" rowspan="3">0.41</td><td align="left" valign="middle" rowspan="3">2.54 (201%)</td><td align="left" valign="middle" rowspan="3">0.56</td><td align="left" valign="middle" rowspan="3">0.34 (26.90%)</td><td align="left">t = 3.63</td></tr><tr><td align="left">p = 0.002</td></tr><tr><td align="left">Significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment + ALA (IV)</bold></td><td align="left" valign="middle" rowspan="3">1.87 (148%)</td><td align="left" valign="middle" rowspan="3">0.11</td><td align="left" valign="middle" rowspan="3">2.10 (167%)</td><td align="left" valign="middle" rowspan="3">0.23</td><td align="left" valign="middle" rowspan="3">0.23 (18.30%)</td><td align="left">t = 6.05</td></tr><tr><td align="left">p = 0.001</td></tr><tr><td align="left">Significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment + ALA + VitC (V)</bold></td><td align="left" valign="middle" rowspan="3">2.10 (167%)</td><td align="left" valign="middle" rowspan="3">0.74</td><td align="left" valign="middle" rowspan="3">2.01 (159%)</td><td align="left" valign="middle" rowspan="3">0.56</td><td align="left" valign="middle" rowspan="3">−0.08 (6.30%)</td><td align="left">t = 1.74</td></tr><tr><td align="left">p = 0.09</td></tr><tr><td align="left">Not Significant</td></tr></tbody></table></table-wrap><fig id="fig0015"><label>Chart 3</label><caption><p>Comparison of levels of Malonyldialdehyde (MDA) on different methods of treatment.</p></caption><alt-text id="at0015">Chart 3</alt-text><graphic xlink:href="pl3"></graphic></fig></p><p id="par0315">The mean levels of total antioxidants on admission compared with those on discharge, showed a decrease in levels on admission in all groups and the levels improved significantly in group III(0.19(11.3%)) and group V(0.52(31.1%)) cases after supplementation of vitamin C and the combination (vitamin C + AlA) respectively (<xref rid="tbl0020" ref-type="table">Table 4</xref>, <xref rid="fig0020" ref-type="fig">Chart 4</xref>, <xref rid="fig0025" ref-type="fig">Chart 5</xref>). Group II and group IV showed no significant improvement.<table-wrap position="float" id="tbl0020"><label>Table 4</label><caption><p>Comparison of levels (in m. moles/l) and the percentage of benefit of different methods of treatment on total anti-oxidant level.</p></caption><alt-text id="at0045">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="2">Groups</th><th colspan="2" align="left">On Admission<hr></hr></th><th colspan="2" align="left">On Discharge<hr></hr></th><th align="left" valign="middle" rowspan="2">Total gain</th><th align="left" valign="middle" rowspan="2">Students Paired t-test</th></tr><tr><th align="left">Mean</th><th align="left">SD</th><th align="left">Mean</th><th align="left">SD</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="3"><bold>Normal (I)</bold></td><td align="left" valign="middle" rowspan="3">1.67</td><td align="left" valign="middle" rowspan="3">0.16</td><td align="left" valign="middle" rowspan="3">1.67</td><td align="left" valign="middle" rowspan="3">0.16</td><td align="left" valign="middle" rowspan="3">0.00</td><td align="left">t = 0.00</td></tr><tr><td align="left">p = 1.00</td></tr><tr><td align="left">Not significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment (II)</bold></td><td align="left" valign="middle" rowspan="3">0.97 (58.9%)</td><td align="left" valign="middle" rowspan="3">0.15</td><td align="left" valign="middle" rowspan="3">0.99 (59.30%)</td><td align="left" valign="middle" rowspan="3">0.16</td><td align="left" valign="middle" rowspan="3">0.02 m(1.10%)</td><td align="left">t = 1.90</td></tr><tr><td align="left">p = 0.07</td></tr><tr><td align="left">Not significant</td></tr><tr><td align="left" valign="middle" rowspan="2"><bold>Routine treatment + VitC (III)</bold></td><td align="left" valign="middle" rowspan="2">1.36 (81.4%)</td><td align="left" valign="middle" rowspan="2">0.30</td><td align="left" valign="middle" rowspan="2">1.55 (76.00%)</td><td align="left" valign="middle" rowspan="2">0.30</td><td align="left" valign="middle" rowspan="2">0.19 (11.30%)</td><td align="left">t = 9.30</td></tr><tr><td align="left">p = 0.001 Significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment + ALA (IV)</bold></td><td align="left" valign="middle" rowspan="3">1.27 (76.0%)</td><td align="left" valign="middle" rowspan="3">0.09</td><td align="left" valign="middle" rowspan="3">1.27 (76.0%)</td><td align="left" valign="middle" rowspan="3">0.09</td><td align="left" valign="middle" rowspan="3">0 (0%)</td><td align="left">t = 0.01</td></tr><tr><td align="left">p = 0.98</td></tr><tr><td align="left">Not significant</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>Routine treatment + ALA + VitC (V)</bold></td><td align="left" valign="middle" rowspan="3">0.92 (55.1%)</td><td align="left" valign="middle" rowspan="3">0.12</td><td align="left" valign="middle" rowspan="3">1.44 (86.20%)</td><td align="left" valign="middle" rowspan="3">0.47</td><td align="left" valign="middle" rowspan="3">0.52 (31.10%)</td><td align="left">t = 4.89</td></tr><tr><td align="left">p = 0.001</td></tr><tr><td align="left">Significant</td></tr></tbody></table></table-wrap><fig id="fig0020"><label>Chart 4</label><caption><p>Comparison of levels of total antioxidants on different methods of treatment.</p></caption><alt-text id="at0020">Chart 4</alt-text><graphic xlink:href="pl4"></graphic></fig><fig id="fig0025"><label>Chart 5</label><caption><p>Percentage of benefit (gain) of different method of treatment on Plasma and RBC Choline esterase, Malonlydialdehyde and total antioxidant levels.</p></caption><alt-text id="at0025">Chart 5</alt-text><graphic xlink:href="pl5"></graphic></fig></p><p id="par0320">The percentage of benefit of treatment on Plasma and RBC Cholinesterases, Malonlydialdehyde and total antioxidant levels is indicated above. Group V showed an overall increase in all the parameters (plasma and RBC cholinesterase being 40.3% and 26.9% respectively and total antioxidant gain being 31.1%), with a decrease in malonyldialdehyde (a negative indicator of oxidative damage). MDA showed improvement in group V cases and their levels decreased on combined supplementation with antioxidants in this group i.e. from 2.10 on admission to 2.01(-0.08, 6.3%) on discharge.</p><p id="par0325">Out of 132 acute amitriptyline poisoning cases studied, the age distribution of male and female showed an almost similar pattern and the mean average age in all groups for the male was 33 and female was 32. The number of male subjects outnumbered the female, with males being 73(55.3%) against 59(44.7%) females. This distribution shows that amitriptyline poisoning is seen more in males (<xref rid="tbl0025" ref-type="table">Table 5</xref>).<table-wrap position="float" id="tbl0025"><label>Table 5</label><caption><p>Demographic Characteristics.</p></caption><alt-text id="at0050">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="3">Groups</th><th colspan="3" align="left">Male<hr></hr></th><th colspan="3" align="left">Female<hr></hr></th><th align="left" valign="middle" rowspan="3">Total Subjects</th></tr><tr><th align="left" valign="middle" rowspan="2">Number</th><th colspan="2" align="left">Age Distribution<hr></hr></th><th align="left" valign="middle" rowspan="2">Number</th><th colspan="2" align="left">Age Distribution<hr></hr></th></tr><tr><th align="left">Mean</th><th align="left">SD</th><th align="left">Mean</th><th align="left">SD</th></tr></thead><tbody><tr><td align="left"><bold>Normal (I)</bold></td><td align="left">16</td><td align="left">30.92</td><td align="left">8.46</td><td align="left">14</td><td align="left">33.56</td><td align="left">16.87</td><td align="left">30</td></tr><tr><td align="left"><bold>Routine treatment (II)</bold></td><td align="left">18</td><td align="left">34.13</td><td align="left">9.54</td><td align="left">12</td><td align="left">30.00</td><td align="left">6.53</td><td align="left">30</td></tr><tr><td align="left"><bold>Routine treatment + VitC (III)</bold></td><td align="left">12</td><td align="left">31.85</td><td align="left">10.96</td><td align="left">9</td><td align="left">30.93</td><td align="left">12.40</td><td align="left">21</td></tr><tr><td align="left"><bold>Routine treatment + ALA (IV)</bold></td><td align="left">13</td><td align="left">33.00</td><td align="left">11.41</td><td align="left">14</td><td align="left">29.40</td><td align="left">11.25</td><td align="left">27</td></tr><tr><td align="left"><bold>Routine treatment + ALA + VitC (V)</bold></td><td align="left">14</td><td align="left">32.67</td><td align="left">11.87</td><td align="left">10</td><td align="left">34.75</td><td align="left">15.62</td><td align="left">24</td></tr><tr><td align="left"><bold>Total</bold></td><td align="left">73 (55.30%)</td><td align="left"></td><td align="left"></td><td align="left">59 (44.70%)</td><td align="left"></td><td align="left"></td><td align="left">132</td></tr></tbody></table></table-wrap></p><p id="par0330">The results also showed that the regeneration or reactivation of plasma Cholinesterase was more rapid than RBC Cholinesterase (<xref rid="fig0005" ref-type="fig">Chart 1</xref>, <xref rid="fig0010" ref-type="fig">Chart 2</xref>). The base levels of both RBC and plasma Cholinesterase remained higher in all groups (<xref rid="tbl0005" ref-type="table">Tables 1,2</xref>, <xref rid="fig0005" ref-type="fig">Chart 1, 2</xref>). In our study, we observed that the effect of supplementation of vitamin C was higher in group III and the effect of supplementation of the combination (i.e. vitamin C + AlA) was greatest in group V (<xref rid="fig0025" ref-type="fig">Chart 5</xref>).</p></sec><sec id="sec0100"><label>5</label><title>Discussion</title><p id="par0335">The main objective of the present study was to determine the efficacy of vitamin C and alpha lipoic acid supplementation to routine standard treatment in acute amitriptyline poisoning cases. The presence of an increased oxidative stress was noticed in these acutely poisoned cases during the study. We chose to supplement vitamin C and alpha lipoic acid for all poisoned patients, vide their major role in ameliorating in vivo free radical damage. Antioxidants broadly fall into 2 classes; those of the Preventive antioxidants, which reduce the rate of chain initiation, (e.g.) catalase and other peroxidases; and the Chain breaking antioxidants which interfere with chain propagation (e.g.) vitamin C and E. Vitamin C reacts rapidly with oxygen free radicals, and are widely accepted antioxidant compounds for their biological activity [<xref rid="bib0140" ref-type="bibr">28</xref>,<xref rid="bib0145" ref-type="bibr">29</xref>]. Alpha lipoic acid in addition to its own antioxidant properties also recycles vitamin C and E thereby enhancing their availability in both aqueous phase (cytosol) and lipid phase (cell membrane). Also alpha lipoic acid dissolves both in lipid and water and acts effectively in both phases.</p><p id="par0340">The mechanism of action of amitriptyline on acetylcholinesterase (AchE) indicates that it interacts with a moiety of hydroxyl group on serine in the active (esteric) site of the enzyme, thereby impeding the action of the latter in physiological substrates. This leads to a profound reduction in their levels by conversion to a lesser active form. RBC and Plasma cholinestrase showed significant improvement in all groups after supplementation with antioxidants, with maximum being in Group V. Hence the increase in RBC and plasma cholinesterase may be due to the effect of treatment with oximes, in all groups of acute poisoning cases. The supplementation of vitamin C and alpha lipoic acid may not have had a direct effect in the improvement of RBC and plasma cholinestrase enzymes, and it would be interesting to further study whether the reduction in oxidative stress and increase in total antioxidant status of acute amitriptyline poisoning patients have any influence in reactivation or de novo synthesis of RBC and plasma cholinesterase.</p><p id="par0345">We observed that the lipid peroxidation (LPO) activity was high in all groups of acute poisoning cases, when compared to normal individual indicating oxidative damage in them. Even after supplementation of vitamin C and alpha lipoic acid alone, the MDA levels remained high, except in group V cases. These results suggests that there is considerable oxidative damage occurring in all acute amitriptyline poisoning cases, our results are in agreement with earlier studies which reported increased LPO activity in acute amitriptyline poisoning. It has been established in animals as well as in humans that serum concentrations of lipid peroxidation products (LPPs) increase in pulmonary inflammation [<xref rid="bib0150" ref-type="bibr">30</xref>]. The clinical manifestation of acute amitriptyline poisoning were pulmonary edema, pulmonary infarction, hence the increased MDA may be due to the pulmonary disorder manifestations of the poisoning.</p><p id="par0350">The results for total antioxidants showed significant increase in Group III and Group V acute amitriptyline poisoning cases who received maximum supplementation with alpha lipoic acid. The increase in total antioxidant levels in these patients is a good sign as these antioxidants are believed to neutralize the ROS, and thereby reduce the oxidative stress. The exact mechanism for increase in total antioxidants after supplementation of vitamin C and alpha lipoic acid is unclear, further study is required to investigate whether vitamin C and alpha lipoic acid enhances, or recycles the endogenous antioxidants or the increase in total antioxidant levels were due to the direct supplementation effect of vitamin C and alpha lipoic acid. As the total antioxidant levels significantly improve, this in turn will improve the faster recovery of these patients, and also reduce long term side effects such as Amitriptyline induced delayed polyneuropathy (AIDP).</p><p id="par0355">Though each case of acute amitriptyline poisoning is unique, the onset, severity and duration of poisoning, are determined by the dose, rate of exposure, physical and chemical properties of amitriptyline. In this study Group V cases showed maximum effect, the reasons probably would be the combination of antioxidant and stay of these patients in IMCU and poison centre was maximum (5–13 days). Hence they received the symptomatic treatment more than other groups, and also the supplementation of vitamin C and alpha lipoic acid was greatest in this group. A major drawback of the study was the number of subjects included in each group, and the exact levels and time since consumption being unknown. A long term follow of these subjects for any rebound in the oxidative stress or drop in antioxidant levels is warranted. Furthermore, the exact pharmacological mechanism by which the antioxidant supplementation with vitamin C and alpha lipoic acid help in reducing the oxidative stress also needs to be studied.</p><p id="par0360">Oral supplementation of alpha lipoic acid for longer period will enhance the total antioxidant levels, and decrease the oxidative stress. It would be interesting to study the supplement of vitamin C and alpha lipoic acid to chronic amitriptyline poisoning cases. Also we suggest that I.V. administration of vitamin C and alpha lipoic acid would be more beneficial to acute amitriptyline poisoning cases.</p></sec><sec id="sec0105"><label>6</label><title>Conclusion</title><p id="par0365">Antioxidants levels were increased with treatment after supplementation with vitamin C and alpha lipoic acid. We suggest that antioxidant status of acute amitriptyline poisoning cases should be considered for more effective recovery and that diets low in antioxidants may render the recovery slow [<xref rid="bib0155" ref-type="bibr">31</xref>].</p><p id="par0370">This study provides quantitative recommendations for the intake of vitamin C and alpha lipoic acid for fast recovery in acute amitriptyline poisoning cases. It also showed that oral supplementation with vitamin C and alpha lipoic acid to acute amitriptyline poisoning cases considerably reduced the oxidative stress, and it also enhanced the total antioxidant levels of these patients. This will also facilitate in reducing the number of days of stay in intensive care units of these poisoning patients, and also supplementation of vitamin C and alpha lipoic acid reduces the long-term side effects of the drug such as Amitriptyline induced delayed Neuropathy (AIDN).</p><p id="par0375">The maximum effect of supplementation of vitamin C and alpha lipoic acid was in Group V (Routine standard treatment + vitamin C + alpha lipoic acid), who received the maximum dosage of vitamin C and alpha lipoic acid (5–13 days). It is clear that the supplementation should be for a longer period to have the maximum beneficial effect (reduced oxidative stress and increased total antioxidant status). In our opinion oral supplementation will be more effective for chronic amitriptyline poison cases for a longer duration and for acute amitriptyline poisoning cases intravenous route will be more effective.</p><p id="par0380">The recovery and regeneration of plasma Cholinesterase were rapid when compared to RBC Cholinesterase in all groups of acute amitriptyline poisoning cases. The average age of acute amitriptyline poisoning cases were 33 for male and 32 for female, and this study shows that the amitriptyline poisoning is seen more in males than in females.</p></sec><sec id="sec0110"><title>Conflict of interest statement</title><p id="par0385">We would like to mention that there is no any conflict of interest, no financial disclosures to make and no any non-financial interest and relationship, with regard to the below mentioned research work.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><label>1</label><element-citation publication-type="book" id="sbref0005"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>C.</given-names></name><name><surname>King</surname><given-names>R.</given-names></name><name><surname>Weisz</surname><given-names>J.</given-names></name><name><surname>Schopler</surname><given-names>J.</given-names></name></person-group><chapter-title>Introduction to Psychology</chapter-title><edition>7th ed.</edition><year>1986</year><publisher-name>McGraw-Hill</publisher-name><publisher-loc>New York</publisher-loc></element-citation></ref><ref id="bib0010"><label>2</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>W.</given-names></name><name><surname>Litovitz</surname><given-names>T.</given-names></name><name><surname>Rodgers</surname><given-names>G.</given-names></name><name><surname>Klein-Schwartz</surname><given-names>W.</given-names></name><name><surname>Reid</surname><given-names>N.</given-names></name><name><surname>Youniss</surname><given-names>J.</given-names></name></person-group><article-title>Annual report of the american association of poison control centers toxic exposure surveillance system</article-title><source>Am. J. Emerg. Med.</source><volume>23</volume><issue>5</issue><year>2004</year><fpage>589</fpage><lpage>666</lpage><comment>2005</comment></element-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="book" id="sbref0015"><person-group person-group-type="author"><name><surname>Jayashree</surname><given-names>G.</given-names></name></person-group><chapter-title>Textbook of Pharmaceutical Chemistry</chapter-title><edition>5th ed.</edition><year>2012</year><publisher-name>S Chand & Co Ltd</publisher-name></element-citation></ref><ref id="bib0020"><label>4</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Deavall</surname><given-names>D.</given-names></name><name><surname>Martin</surname><given-names>E.</given-names></name><name><surname>Horner</surname><given-names>J.</given-names></name><name><surname>Roberts</surname><given-names>R.</given-names></name></person-group><article-title>Drug-induced oxidative stress and toxicity</article-title><source>J. Toxicol.</source><volume>2012</volume><year>2012</year><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="bib0025"><label>5</label><element-citation publication-type="book" id="sbref0025"><person-group person-group-type="author"><name><surname>WHO</surname></name></person-group><chapter-title>The International Programme on Chemical Safety (IPCS) Monographs - Analytical and Toxicological Data (6.3)</chapter-title><year>2018</year><ext-link ext-link-type="uri" xlink:href="http://www.who.int/ipcs/publications/training_poisons/basic_analytical_tox/en/index7.htm" id="intr0010">http://www.who.int/ipcs/publications/training_poisons/basic_analytical_tox/en/index7.htm</ext-link></element-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>T.</given-names></name><name><surname>Maruguchi</surname><given-names>H.</given-names></name><name><surname>Nakao</surname><given-names>A.</given-names></name><name><surname>Nakayama</surname><given-names>S.</given-names></name></person-group><article-title>Unusual complications from amitriptyline intoxication</article-title><source>BMJ Case Rep.</source><year>2017</year><comment>bcr-2017-219257</comment></element-citation></ref><ref id="bib0035"><label>7</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>K.</given-names></name><name><surname>Kearney</surname><given-names>T.</given-names></name><name><surname>Dyer</surname><given-names>J.</given-names></name><name><surname>Benowitz</surname><given-names>N.</given-names></name><name><surname>Blanc</surname><given-names>P.</given-names></name></person-group><article-title>Seizures associated with poisoning and drug overdose</article-title><source>Am. J. Emerg. Med.</source><volume>11</volume><issue>6</issue><year>1993</year><fpage>565</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">8192750</pub-id></element-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Guloglu</surname><given-names>C.</given-names></name><name><surname>Orak</surname><given-names>M.</given-names></name><name><surname>Ustundag</surname><given-names>M.</given-names></name><name><surname>Altunci</surname><given-names>Y.</given-names></name></person-group><article-title>Analysis of amitriptyline overdose in emergency medicine</article-title><source>Emerg. Med. J.</source><volume>28</volume><issue>4</issue><year>2010</year><fpage>296</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">20923818</pub-id></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Halliwell</surname><given-names>B.</given-names></name></person-group><article-title>Oxidants and human disease: some new concepts</article-title><source>Faseb J.</source><volume>1</volume><issue>5</issue><year>1987</year><fpage>358</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">2824268</pub-id></element-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Cheeseman</surname><given-names>K.</given-names></name><name><surname>Slater</surname><given-names>T.</given-names></name></person-group><article-title>An introduction to free radical biochemistry</article-title><source>Br. Med. Bull.</source><volume>49</volume><issue>3</issue><year>1993</year><fpage>481</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">8221017</pub-id></element-citation></ref><ref id="bib0055"><label>11</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Pryor</surname><given-names>W.</given-names></name></person-group><article-title>Lipid peroxidation in biological systems</article-title><source>Free Radic. Biol. Med.</source><volume>6</volume><issue>2</issue><year>1989</year><fpage>225</fpage></element-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Benzie</surname><given-names>I.</given-names></name><name><surname>Strain</surname><given-names>J.</given-names></name></person-group><article-title>The ferric reducing ability of plasma (FRAP) as a measure of “Antioxidant power”: the FRAP assay</article-title><source>Anal. Biochem.</source><volume>239</volume><issue>1</issue><year>1996</year><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">8660627</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Bandegi</surname><given-names>L.</given-names></name><name><surname>Anvari</surname><given-names>M.</given-names></name><name><surname>Vakili</surname><given-names>M.</given-names></name><name><surname>Khoradmehr</surname><given-names>A.</given-names></name><name><surname>Mirjalili</surname><given-names>A.</given-names></name><name><surname>Talebi</surname><given-names>A.</given-names></name></person-group><article-title>Effects of antidepressants on parameters, melondiadehyde, and diphenyl-2-picryl-hydrazyl levels in mice spermatozoa</article-title><source>Int. J. Reprod. Biomed.</source><volume>16</volume><issue>6</issue><year>2018</year><fpage>365</fpage><lpage>372</lpage></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Smirnoff</surname><given-names>N.</given-names></name></person-group><article-title>l-Ascorbic acid biosynthesis</article-title><source>Vitam. Horm.</source><year>2001</year><fpage>241</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">11153268</pub-id></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Padayatty</surname><given-names>S.</given-names></name><name><surname>Katz</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Eck</surname><given-names>P.</given-names></name><name><surname>Kwon</surname><given-names>O.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name></person-group><article-title>Vitamin C as an antioxidant: evaluation of its role in disease prevention</article-title><source>J. Am. Coll. Nutr.</source><volume>22</volume><issue>1</issue><year>2003</year><fpage>18</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">12569111</pub-id></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Simioni</surname><given-names>C.</given-names></name><name><surname>Zauli</surname><given-names>G.</given-names></name><name><surname>Martelli</surname><given-names>A.</given-names></name><name><surname>Vitale</surname><given-names>M.</given-names></name><name><surname>Sacchetti</surname><given-names>G.</given-names></name><name><surname>Gonelli</surname><given-names>A.</given-names></name></person-group><article-title>Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging</article-title><source>Oncotarget</source><volume>9</volume><issue>24</issue><year>2018</year></element-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Ganguly</surname><given-names>S.</given-names></name><name><surname>Chandra</surname><given-names>A.</given-names></name><name><surname>Chatterjee</surname><given-names>I.</given-names></name></person-group><article-title>Pathobiology of cigarette smoke-induced invasive cancer of the renal pelvis and its prevention by vitamin C</article-title><source>Toxicol. Rep.</source><volume>5</volume><year>2018</year><fpage>1002</fpage><lpage>1010</lpage><pub-id pub-id-type="pmid">30338226</pub-id></element-citation></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Ganguly</surname><given-names>S.</given-names></name><name><surname>Chandra</surname><given-names>A.</given-names></name><name><surname>Chattopadhyay</surname><given-names>D.</given-names></name><name><surname>Chatterjee</surname><given-names>I.</given-names></name></person-group><article-title>p-Benzoquinone initiates non-invasive urothelial cancer through aberrant tyrosine phosphorylation of EGFR, MAP kinase activation and cell cycle deregulation: Prevention by vitamin C</article-title><source>Toxicol. Rep.</source><volume>4</volume><year>2017</year><fpage>296</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">28959653</pub-id></element-citation></ref><ref id="bib0095"><label>19</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>S.</given-names></name><name><surname>Gupta</surname><given-names>V.</given-names></name><name><surname>Ansari</surname><given-names>M.</given-names></name><name><surname>Siddiqi</surname><given-names>N.</given-names></name><name><surname>Sharma</surname><given-names>B.</given-names></name></person-group><article-title>Vitamin C acts as a hepatoprotectant in carbofuran treated rat liver slices in vitro</article-title><source>Toxicol. Rep.</source><volume>4</volume><year>2017</year><fpage>265</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">28959648</pub-id></element-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>K.</given-names></name><name><surname>dos Anjos</surname><given-names>L.</given-names></name><name><surname>Araújo</surname><given-names>A.</given-names></name><name><surname>Luz</surname><given-names>W.</given-names></name><name><surname>Kauffmann</surname><given-names>N.</given-names></name><name><surname>Braga</surname><given-names>D.</given-names></name></person-group><article-title>Ascorbic acid prevents chloroquine-induced toxicity in inner glial cells</article-title><source>Toxicol. Vitr.</source><volume>56</volume><year>2019</year><fpage>150</fpage><lpage>155</lpage></element-citation></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Hager</surname><given-names>K.</given-names></name><name><surname>Marahrens</surname><given-names>A.</given-names></name><name><surname>Kenklies</surname><given-names>M.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name><name><surname>Münch</surname><given-names>G.</given-names></name></person-group><article-title>Erratum to “Alpha-lipoic acid as a new treatment option for Alzheimer type dementia” [Arch. Gerontol. Geriatr. 32 (2001) 275–282]</article-title><source>Arch. Gerontol. Geriatr.</source><volume>51</volume><issue>1</issue><year>2010</year><fpage>110</fpage></element-citation></ref><ref id="bib0110"><label>22</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Smeyne</surname><given-names>M.</given-names></name><name><surname>Smeyne</surname><given-names>R.</given-names></name></person-group><article-title>Glutathione metabolism and Parkinson’s disease</article-title><source>Free Radic. Biol. Med.</source><volume>62</volume><year>2013</year><fpage>13</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">23665395</pub-id></element-citation></ref><ref id="bib0115"><label>23</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Venkataraman</surname><given-names>B.V.</given-names></name><name><surname>Naga Rani</surname><given-names>M.A.</given-names></name><name><surname>Andrade</surname><given-names>C.</given-names></name><name><surname>Joseph</surname><given-names>T.</given-names></name></person-group><article-title>Improved colorimetric method for cholinesterase activity</article-title><source>Indian J. Physiol. Pharmacol.</source><volume>37</volume><year>1993</year><fpage>82</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">8449554</pub-id></element-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="book" id="sbref0120"><person-group person-group-type="author"><name><surname>Burtis</surname><given-names>C.</given-names></name><name><surname>Ashwood</surname><given-names>E.</given-names></name><name><surname>Tietz</surname><given-names>N.</given-names></name></person-group><chapter-title>Tietz Textbook of Clinical Chemistry</chapter-title><year>1999</year><publisher-name>Harcourt brace & company asia Pte Ltd</publisher-name><publisher-loc>Singapore</publisher-loc></element-citation></ref><ref id="bib0125"><label>25</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>N.</given-names></name><name><surname>Rice-Evans</surname><given-names>C.</given-names></name></person-group><article-title>Factors influencing the antioxidant activity determined by the ABTS•+radical cation assay</article-title><source>Free Radic. Res.</source><volume>26</volume><issue>3</issue><year>1997</year><fpage>195</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">9161842</pub-id></element-citation></ref><ref id="bib0130"><label>26</label><element-citation publication-type="book" id="sbref0130"><person-group person-group-type="author"><name><surname>Nikalje</surname><given-names>A.</given-names></name><name><surname>Bhosale</surname><given-names>D.</given-names></name></person-group><series>A Handbook of ChrOmatography</series><volume>13</volume><year>2017</year><fpage>678</fpage><lpage>682</lpage></element-citation></ref><ref id="bib0135"><label>27</label><element-citation publication-type="book" id="sbref0135"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>R.</given-names></name></person-group><chapter-title>Basic Analytical Toxicology</chapter-title><year>1995</year><publisher-name>WHO</publisher-name><publisher-loc>Geneva</publisher-loc></element-citation></ref><ref id="bib0140"><label>28</label><mixed-citation publication-type="other" id="oref0140">W.H. Sebrell, R.S. Harris (Eds.), 2nd ed. Academic, New York, 1972.</mixed-citation></ref><ref id="bib0145"><label>29</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Bielski</surname><given-names>B.H.J.</given-names></name><name><surname>Comstock</surname><given-names>D.A.</given-names></name><name><surname>Bowen</surname><given-names>R.A.J.</given-names></name></person-group><article-title>Reaction of Vitamin C& E with oxygen free radical</article-title><source>An. Chem. Soc.</source><volume>93</volume><year>1971</year><fpage>5624</fpage><lpage>5629</lpage></element-citation></ref><ref id="bib0150"><label>30</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Demling</surname><given-names>R.</given-names></name><name><surname>Lalonde</surname><given-names>C.</given-names></name></person-group><article-title>Relationship between lung injury and lung lipid peroxidation caused by recurrent endotoxemia</article-title><source>An. Rev. Respir Dis.</source><volume>139</volume><year>1989</year><fpage>1118</fpage><lpage>1124</lpage></element-citation></ref><ref id="bib0155"><label>31</label><element-citation publication-type="book" id="sbref0155"><person-group person-group-type="author"><name><surname>Martell</surname><given-names>A.</given-names></name></person-group><chapter-title>Chelates of Ascorbic Acid</chapter-title><year>1982</year><publisher-name>Ascorbic Acid: Chemistry, Metabolism, and Uses</publisher-name><fpage>153</fpage><lpage>178</lpage></element-citation></ref></ref-list><sec id="sec0120" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="par0395">The following is Supplementary data to this article:<supplementary-material content-type="local-data" id="upi0005"><media xlink:href="mmc1.docx"></media></supplementary-material></p></sec><fn-group><fn id="sec0115" fn-type="supplementary-material"><label>Appendix A</label><p id="par0390">Supplementary material related to this article can be found, in the online version, at doi:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxrep.2019.04.002" id="intr0005">https://doi.org/10.1016/j.toxrep.2019.04.002</ext-link>.</p></fn></fn-group></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0008320 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0008320 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |